Clinical trial

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

NCT01482156

Study summary

ClinicalTrials.gov

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention RAD001 + BEZ235 Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE1

Conditions

Advanced Solid Tumorsunresolved

Metastatic Breast Cancerunresolved

Metastatic Renal Cell Carcinomaunresolved

Interventions

RAD001 + BEZ235DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

St LouisMissouri, United States1 CharlestonSouth Carolina, United States1 BordeauxFrance1 BarcelonaCatalonia, Spain1 AucklandNew Zealand1 FayettevilleArkansas, United States1 WilrijkBelgium1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01482156 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.